Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.68 |
| ▸ | HRH1 | P35367 | 18/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 17/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227691 | 0.85 | HTR3A (0.72) | HTR3AHRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL14198327 | 0.81 | HTR3A (0.71) | HTR3AHRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL7431298 | 0.81 | HTR3A (1.00) | HTR3AHRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL5227740 | 0.81 | HTR3A (0.61) | HTR3AHRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL5229655 | 0.80 | HRH1 (0.73) | HTR3AHRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL10337972 | 0.80 | HRH1 (0.73) | HTR3AHRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL31553435 | 0.80 | HRH1 (1.00) | HTR3AHRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL5226378 | 0.80 | HRH1 (1.00) | HTR3AHRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL8881095 | 0.79 | HTR3A (0.86) | HTR3AHRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL5227745 | 0.79 | HTR3A (0.67) | HTR3AHRH1CYP2D6KCNH2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1564212-B1 | PROCESS AND INTERMEDIATES FOR OBTAINING 1-(1H-BENZIMIDAZOL-2-YL)-4-(PYRIMIDIN-2-YLAMINO)PIPERIDINE DERIVATIVES | RAGACTIVES SL (ES) | 2007-12-12 | — | — | EP | claimed |
| US-20050228006-A1 | Process and intermediates for obtaining 1-(1H-benzimidazol-2-YL)-4-(2-aminopyrimidine)piperidine derivatives | RAGACTIVES, S.L. | 2005-10-13 | — | — | US | claimed |
| EP-1564212-A1 | METHOD AND INTERMEDIA USED TO OBTAIN DERIVATIVES OF 1-(1H- BENZIMIDAZOLE-2-YL)-4-(2-AMINOPYRIMIDINE)PIPERIDINE | Ragactives, S.L. (ES) | 2005-08-17 | — | — | EP | claimed |
| EP-1564212-B1 | PROCESS AND INTERMEDIATES FOR OBTAINING 1-(1H-BENZIMIDAZOL-2-YL)-4-(PYRIMIDIN-2-YLAMINO)PIPERIDINE DERIVATIVES | RAGACTIVES SL (ES) | 2007-12-12 | — | — | EP | disclosed |
| US-20050228006-A1 | Process and intermediates for obtaining 1-(1H-benzimidazol-2-YL)-4-(2-aminopyrimidine)piperidine derivatives | RAGACTIVES, S.L. | 2005-10-13 | — | — | US | disclosed |
| EP-1564212-A1 | METHOD AND INTERMEDIA USED TO OBTAIN DERIVATIVES OF 1-(1H- BENZIMIDAZOLE-2-YL)-4-(2-AMINOPYRIMIDINE)PIPERIDINE | Ragactives, S.L. (ES) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228006-A1 | Process and intermediates for obtaining 1-(1H-benzimidazol-2-YL)-4-(2-aminopyrimidine)piperidine derivatives | IL2, IL4, IL4I1 | HTR3A 921/4885HRH1 37/4885CYP2D6 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.